welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Health

Health

BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

80% Informative

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on June 3 and set a price target of $ 17.00 .

RLY-2608 is the first known investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3K.

VR Score

78

Informative language

77

Neutral language

31

Article tone

formal

Language

English

Language complexity

65

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links